<DOC>
	<DOCNO>NCT01557777</DOCNO>
	<brief_summary>Open-label extension study navitoclax subject chronic lymphocytic leukemia ( CLL ) .</brief_summary>
	<brief_title>Open-label Extension Study Navitoclax Subjects With Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description>This open-label extension study navitoclax subject chronic lymphocytic leukemia ( CLL ) .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Navitoclax</mesh_term>
	<criteria>The subject dose Arm C ABT4710n study , discontinue reason prior study closure investigator believe continued treatment navitoclax best interest subject The subject must meet defined hematology coagulation lab criterion specify protocol The subject must meet defined chemistry criterion specify protocol Women childbearing potential men must agree use adequate contraception ( per protocol ) prior study entry , duration study participation 90 day follow completion therapy The subject capable understanding comply parameter outline protocol able sign Informed Consent Form The subject discontinue navitoclax administration Arm C ABT4710n study reason disease progression , Adverse Event toxicity , withdrawal consent Investigator decision prior study completion . The subject medical condition opinion investigator place subject unacceptably high risk toxicity . The subject lactating pregnant female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>